# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $...
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform
Jefferies analyst Roger Song upgrades CytomX Therapeutics (NASDAQ:CTMX) from Hold to Buy and raises the price target from $2...